8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A critical analysis of the SUNRISE-1 trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for lemborexant in insomnia.
A detailed breakdown of SUNRISE-1's randomization, blinding, endpoint definitions, comparator rationale, and statistical framework for lemborexant in insomnia.
Health-economic analysis of lemborexant based on SUNRISE-1 trial data: cost per QALY, payer coverage patterns, WAC vs net pricing, and patient-level value calculations for insomnia treatment.
Deep-dive into SUNRISE-1 long-term extension findings for lemborexant in insomnia: durability of sleep onset latency improvements, safety signals over 12 months, and what the follow-up data reveal about sustained efficacy.
Deep-dive into SUNRISE-1 trial results for lemborexant (Dayvigo) in insomnia: primary and secondary endpoints, effect sizes, confidence intervals, time-course data, and response distribution analysis.
Pre-specified and post-hoc subgroup analyses from the SUNRISE-1 trial of lemborexant for insomnia, examining differential response by age, sex, BMI, race, and baseline severity.
A deep-dive into the SUNRISE-1 randomized controlled trial that tested lemborexant against placebo and zolpidem for insomnia, leading to FDA approval of a dual orexin receptor antagonist.
A clinical deep-dive into the SUNRISE-1 trial of lemborexant for insomnia, examining what the results mean for real-world prescribing decisions, guideline updates, and patient selection beyond the abstract.